Display options
Cite
Dahlström EH, Saksi J, Forsblom C, et al. The Low-Expression Variant of . Diabetes. 2021;70(10):2391-2401doi: 10.2337/db21-0056.
Dahlström, E. H., Saksi, J., Forsblom, C., Uglebjerg, N., Mars, N., Thorn, L. M., Harjutsalo, V., Rossing, P., Ahluwalia, T. S., Lindsberg, P. J., Sandholm, N., Groop, P. H. (2021). The Low-Expression Variant of . Diabetes, 70(10), 2391-2401. https://doi.org/10.2337/db21-0056
Dahlström, Emma H, et al. "The Low-Expression Variant of ." Diabetes vol. 70,10 (2021): 2391-2401. doi: https://doi.org/10.2337/db21-0056
Dahlström EH, Saksi J, Forsblom C, Uglebjerg N, Mars N, Thorn LM, Harjutsalo V, Rossing P, Ahluwalia TS, Lindsberg PJ, Sandholm N, Groop PH. The Low-Expression Variant of . Diabetes. 2021 Oct;70(10):2391-2401. doi: 10.2337/db21-0056. Epub 2021 Jul 09. PMID: 34244239.
Copy Download .nbib Format: NLM
Share it on

Diabetes. 2021 Oct;70(10):2391-2401. doi: 10.2337/db21-0056. Epub 2021 Jul 09.

The Low-Expression Variant of .

Diabetes

Emma H Dahlström, Jani Saksi, Carol Forsblom, Nicoline Uglebjerg, Nina Mars, Lena M Thorn, Valma Harjutsalo, Peter Rossing, Tarunveer S Ahluwalia, Perttu J Lindsberg, Niina Sandholm, Per-Henrik Groop,

Affiliations

  1. Folkhälsan Research Center, Helsinki, Finland.
  2. Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  3. Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  4. Neurology, Neurocenter, Helsinki University Hospital, and Clinical Neurosciences, University of Helsinki, Helsinki, Finland.
  5. Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  6. Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  7. Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  8. National Institute for Health and Welfare, Helsinki, Finland.
  9. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  10. The Bioinformatics Center, Department of Biology, University of Copenhagen, Copenhagen, Denmark.

PMID: 34244239 DOI: 10.2337/db21-0056

Abstract

Fatty acid binding protein 4 (FABP4) is implicated in the pathogenesis of cardiometabolic disorders. Pharmacological inhibition or genetic deletion of FABP4 improves cardiometabolic health and protects against atherosclerosis in preclinical models. As cardiovascular disease (CVD) is common in type 1 diabetes, we examined the role of FABP4 in the development of complications in type 1 diabetes, focusing on a functional, low-expression variant (rs77878271) in the promoter of the

© 2021 by the American Diabetes Association.

Publication Types